A Pill That Nearly Doubles Survival: Inside the Landmark FDA Approval That's Changing Pancreatic Cancer Forever

 

A Pill That Nearly Doubles Survival: Inside the Landmark FDA Approval That's Changing Pancreatic Cancer Forever

## A Quiet Revolution in a Pill Bottle

On a Wednesday morning in late August, the Food and Drug Administration did something that, for the thousands of Americans living with metastatic pancreatic cancer, felt nothing short of miraculous. It approved a pill that nearly doubles survival time for patients with one of the deadliest forms of cancer — a disease that has, for decades, stubbornly resisted almost every treatment thrown at it.

The drug is called **daraxonrasib** — brand name **Rasonque** — and it represents the first approved therapy in a new class of drugs that target the RAS protein, a mutated driver of tumor growth found in more than 90% of pancreatic cancer cases. For patients whose cancer had stopped responding to prior treatment, the results were striking: those taking the new drug lived a median of **13.2 months** compared with just **6.7 months** for those receiving standard chemotherapy.

"This is not a cure," said Dr. Pashtoon Kasi of City Hope Orange County, "but it's the best option we've ever had".

For a disease that kills more than 52,000 Americans each year and has a five-year survival rate of just 13%, that's not just progress. It's a revolution.

---

## The Problem: Why Pancreatic Cancer Has Been So Hard to Beat

Pancreatic cancer has long been one of medicine's most formidable opponents. It's notoriously difficult to detect before it spreads, and once it metastasizes, treatment options have been limited and largely ineffective.

The American Cancer Society estimates about **67,000 new cases** will be diagnosed in the United States this year, and more than **52,000 people will die** from the disease. The five-year survival rate — just 13% — has barely budged in decades.

For years, researchers have known that mutations in the RAS gene family are the primary drivers of pancreatic cancer. But targeting RAS with drugs proved extraordinarily challenging. The protein's structure made it nearly impossible for drugs to bind to it, earning RAS the label **"undruggable"**.

"We have known for a long time that RAS mutations are the key drivers, but therapeutically blocking RAS signaling proved extraordinarily challenging," said Dr. Brian Wolpin, who led the clinical trial and directs the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute.

That challenge has finally been overcome.

---

## The Breakthrough: How Daraxonrasib Works

Daraxonrasib is a **first-in-class, oral RAS(ON) multiselective inhibitor**. In plain English: it's a once-daily pill that uses what's essentially a molecular glue to bind to multiple subtypes of the mutated RAS protein, blocking its ability to fuel tumor growth.

The drug's mechanism is elegant in its simplicity. Rather than trying to attack cancer cells broadly — which is what chemotherapy does — daraxonrasib zeroes in on the specific genetic mutation driving the cancer. It's precision medicine at its finest.

"Beyond unprecedented efficacy, daraxonrasib is convenient and appears safe," noted the editors of Gastroendonews. "It can be taken at home rather than infused and has a more favorable toxicity profile".

Where second-line chemotherapy is typically associated with severe side effects like neutropenia, neuropathy, and debilitating fatigue, daraxonrasib's main adverse events are rash, diarrhea, stomatitis, and nausea — manageable enough that **only about 1% of patients discontinued treatment due to toxicity**, compared with 11% on chemotherapy.

---

## The Trial: Data That Changed Everything

The approval was based on results from the **Phase 3 RASolute 302 trial**, a randomized, open-label, multicenter study involving **500 patients** with metastatic pancreatic cancer whose disease had progressed after receiving one prior line of systemic therapy.

Patients were randomly assigned to receive either daraxonrasib or one of several standard chemotherapy regimens chosen by their physicians. The results, presented at the 2026 ASCO Annual Meeting and published in *The New England Journal of Medicine*, were nothing short of historic.

In the overall population, the median overall survival was **13.2 months** with daraxonrasib compared with **6.7 months** with chemotherapy — a hazard ratio of 0.40, representing a **60% reduction in the risk of death**.

At 12 months, **53.2% of patients** in the daraxonrasib arm were still alive, compared with just **17.3%** in the chemotherapy arm.

The drug also significantly improved progression-free survival: patients taking daraxonrasib went a median of **7.2 months** without their cancer worsening, compared with **3.6 months** on chemotherapy. And the objective response rate — meaning tumors shrank or disappeared — was **30%** with daraxonrasib versus **11%** with chemotherapy.

Dr. Brandon Huffman, a gastrointestinal oncologist at Dana-Farber who enrolled patients in the trial, noted that patients were much more likely to stay on treatment with daraxonrasib: "Median dose intensity topped 90%," he said.

---

## The FDA: A Stamp of Approval, Six Months Early

The FDA granted daraxonrasib **breakthrough therapy, orphan drug, and priority review** designations, and approved the drug a remarkable **6.5 months ahead** of its target date.

"It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible," said Acting FDA Commissioner Kyle Diamantas.

The approval was also notable for the speed of the review process. The FDA used its **Real-Time Oncology Review pilot program**, which streamlined data submission prior to the filing of the complete clinical application, and the Assessment Aid, a voluntary submission from the applicant.

The review was conducted under **Project Orbis**, an FDA initiative that provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, the FDA collaborated with **Health Canada**, with the European Medicines Agency and Japan's Pharmaceuticals and Medical Devices Agency serving as official observers.

---

## The Human Impact: Stories Behind the Statistics

The trial data tells one story. But the human stories behind the numbers are what truly matter.

Earlier this year, former Senator **Ben Sasse** (R-Neb.) appeared on CBS's "60 Minutes" and described how he has had less pain while taking daraxonrasib in an expanded access program before the drug's official approval. His public testimony helped generate a surge of interest in the drug and led the FDA to allow "expanded access" for patients who met certain criteria.

For patients like Sasse, the drug isn't just about extending life — it's about improving the quality of the time they have left.

Dr. Pashtoon Kasi of City Hope Orange County captured the sentiment perfectly: "This is not a cure, it's one more option for these patients. But it's the best option we've ever had".

---

## The Future: A New Frontier for Cancer Treatment

The approval of daraxonrasib is not just a victory for pancreatic cancer patients — it's a milestone for cancer research more broadly.

"This drug showed unprecedented results in an area of high unmet need," said Dr. Angelo de Claro, director of the FDA's Oncology Center of Excellence.

Doctors who treat pancreatic cancer hope the drug may usher in more new options for other forms of cancer, with scores of experimental drugs now in development.

"I think this has opened doors for many other companies," Kasi said. "Downstream I think there are going to be a lot more trials looking at this approach in other tumor types".

Revolution Medicines, the Redwood City, California-based drugmaker behind Rasonque, is already studying its technology for several other forms of cancer, including lung cancer.

For patients, the message is clear: the era of RAS being "undruggable" is over. And that opens up a world of possibility.

---

## Frequently Asked Questions (FAQs)

### 1. What is daraxonrasib (Rasonque)?

Daraxonrasib, sold under the brand name Rasonque, is a first-in-class, oral RAS(ON) multiselective inhibitor approved by the FDA on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

### 2. How does daraxonrasib work?

The drug targets mutations in the RAS gene family, which drive tumor growth in more than 90% of pancreatic cancer cases. It uses a molecular glue to bind to multiple RAS subtypes, blocking their ability to fuel tumor growth.

### 3. How effective is it?

In the Phase 3 RASolute 302 trial, patients taking daraxonrasib had a median overall survival of 13.2 months compared with 6.7 months for those receiving standard chemotherapy — a 60% reduction in the risk of death. At 12 months, 53.2% of patients on daraxonrasib were still alive compared with 17.3% on chemotherapy.

### 4. What are the side effects?

The most common adverse events are rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage. Unlike chemotherapy, which is often associated with severe side effects like neutropenia and neuropathy, daraxonrasib has a more favorable toxicity profile.

### 5. Is it a cure?

No. As Dr. Pashtoon Kasi noted, "This is not a cure, it's one more option for these patients. But it's the best option we've ever had".

### 6. Who is eligible for this treatment?

The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

### 7. How was the drug approved so quickly?

The FDA granted the drug breakthrough therapy, orphan drug, and priority review designations, and approved it 6.5 months ahead of its target date. The review used the Real-Time Oncology Review pilot program and Project Orbis, an initiative for concurrent international review.

### 8. What does this mean for other cancers?

Doctors hope the drug may usher in more new options for other forms of cancer, with scores of experimental drugs now in development. Revolution Medicines is already studying its technology for lung cancer and other tumor types.

---

## A Turning Point, Not an Endpoint

The FDA approval of daraxonrasib marks a turning point in the fight against pancreatic cancer — a disease that has, for too long, been a death sentence for far too many.

For the patients who will now have access to this drug, it represents something more than a statistic: it's more time with loved ones, more moments that matter, more hope where there was precious little before.

"Today's approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer," said Acting FDA Commissioner Kyle Diamantas.

But this approval is also a beginning. It's proof that the RAS protein — long considered "undruggable" — can be targeted. It's evidence that precision medicine can work even in the most challenging cancers. And it's a signal to researchers, drugmakers, and patients alike that the future of cancer treatment is not just about more options, but about **better** options.

Dr. Brian Wolpin, who led the trial, put it simply: "The nearly doubling of median overall survival time seen with this targeted treatment represents meaningful progress for patients where new treatment options are urgently needed".

For the 67,000 Americans who will be diagnosed with pancreatic cancer this year, that progress isn't just meaningful. It's life-changing.

---

## Disclaimer

*This article is for informational and educational purposes only and does not constitute professional medical advice. The information provided is based on publicly available FDA announcements and clinical trial data as of August 27, 2026. Patients should consult with their healthcare providers to determine whether any treatment discussed in this article is appropriate for their individual circumstances. The author is not affiliated with Revolution Medicines, the FDA, or any other entity mentioned in this article.*